Animal funds

Elanco Animal Health Incorporated (NYSE:ELAN) Expected to Report Quarterly Sales of $1.22 Billion

Analysts expect Elanco Animal Health Incorporated (NYSE:ELAN – Get a rating) to post sales of $1.22 billion for the current fiscal quarter, according to Zacks. Four analysts have released earnings estimates for Elanco Animal Health. The lowest sales estimate is $1.21 billion and the highest is $1.23 billion. Elanco Animal Health reported sales of $1.24 billion in the same quarter last year, suggesting a negative 1.6% year-over-year growth rate. The company is expected to release its next quarterly results on Monday, January 1.

According to Zacks, analysts expect Elanco Animal Health to report annual sales of $4.78 billion for the current year, with estimates ranging from $4.77 billion to $4.79 billion. dollars. For the next fiscal year, analysts expect the company to post sales of $4.94 billion, with estimates ranging from $4.90 billion to $4.99 billion. Zacks Investment Research sales calculations are an average based on a survey of sell-side analysts who track Elanco Animal Health.

Elanco Animal Health (NYSE: ELAN – Get a rating) last reported results on Wednesday, February 23. The company reported EPS of $0.21 for the quarter, beating Thomson Reuters consensus estimate of $0.17 by $0.04. The company posted revenue of $1.11 billion in the quarter, versus $1.10 billion expected by analysts. Elanco Animal Health had a positive return on equity of 6.59% and a negative net margin of 9.91%. The company’s revenue for the quarter was down 2.3% year over year. During the same period last year, the company achieved EPS of $0.12.

(A d)

Due to Russian threats, the White House has warned the semiconductor industry of possible material shortages…including helium. Chipmakers are currently sourcing the necessary materials from both Ukraine and Russia, which could further exacerbate the existing helium shortage.

Several analysts have recently commented on ELAN’s stock. Barclays raised its price target on Elanco Animal Health from $30.00 to $32.00 and gave the company an “equal weight” rating in a Monday, February 28 research note. Zacks Investment Research upgraded shares of Elanco Animal Health from a “sell” to a “hold” rating in a Monday, February 28 research report. Five research analysts gave the stock a hold rating and six gave the stock a buy rating. According to MarketBeat data, Elanco Animal Health has an average rating of “Buy” and a consensus target price of $37.63.

Shares of ELAN opened at $27.20 on Tuesday. Elanco Animal Health has a 52-week low of $24.15 and a 52-week high of $37.49. The stock has a market capitalization of $12.87 billion, a price-earnings ratio of -28.33, a PEG ratio of 1.16 and a beta of 0.80. The company has a debt ratio of 0.80, a quick ratio of 1.16 and a current ratio of 1.99. The stock has a fifty-day moving average of $26.38 and a 200-day moving average of $29.49.

In other news, Director David Hoover bought 5,000 shares of the company in a trade dated Tuesday, March 1. The shares were purchased at an average price of $28.66 per share, for a total transaction of $143,300.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, accessible via this hyperlink. Company insiders hold 6.11% of the company’s shares.

Institutional investors and hedge funds have recently increased or reduced their stakes in the company. CKW Financial Group bought a new position in Elanco Animal Health in the fourth quarter worth about $30,000. Herold Advisors Inc. purchased a new stake in shares of Elanco Animal Health during Q3 for $31,000. Clearstead Advisors LLC purchased a new stake in shares of Elanco Animal Health during Q3 for $31,000. First Horizon Advisors Inc. purchased a new stake in shares of Elanco Animal Health during Q3 for $36,000. Finally, Benjamin Edwards Inc. increased its position in Elanco Animal Health shares by 157.1% during the 4th quarter. Benjamin Edwards Inc. now owns 1,427 shares of the company valued at $40,000 after purchasing an additional 872 shares during the period. Institutional investors and hedge funds own 97.90% of the company’s shares.

Company Profile Elanco Animal Health (Get a rating)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures and markets pet and farm animal products. It offers disease prevention products for companion animals, such as parasiticide products and vaccines that protect animals against worms, fleas and ticks under the brand names Seresto, Advantage, Advantix and Advocate; companion animal health therapies for pain, osteoarthritis, ear infections, cardiovascular and dermatological indications in dogs and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides and other products for poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides and other products used in ruminant and swine production under the Rumensin and Baytril brands.

Recommended Stories

Get a Free Copy of Zacks’ Research Report on Elanco Animal Health (ELAN)

For more information on Zacks Investment Research’s research offerings, visit

Earnings history and estimates for Elanco Animal Health (NYSE:ELAN)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Elanco Animal Health right now?

Before you consider Elanco Animal Health, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Elanco Animal Health didn’t make the list.

While Elanco Animal Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here